The secret to a healthy life and longevity? Keep inflammation in check!
Premise Biosystems revolutionizes chronic low-grade inflammation detection with advanced cell-based liquid biopsy technology. Read more
Our cutting-edge technology identifies rare abnormal cells associated with inflammation and immune response from a relative small blood volume enabling the detection of the onset of non-communicable diseases such as cancer, heart attack or stroke. Our innovative approach paves the way for earlier interventions and improved patient outcomes.
Our Professional Leads
Dr. Suparerk Borwornpinyo
CEO and Co-Founder
Dr. Stefan Schreier
Co-Founder
Our Goal in 2030
We aim to build a new healthcare database based on circulating rare cell data with utilizing AI tools to analyze rare cell images and generate detailed patient reports.
With this integration of AI and big data, we aim to enhance diagnostic accuracy and streamline patient care that can save millions of lives.